125 related articles for article (PubMed ID: 37344371)
1. Reply letter to "Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design".
Hadigal S; Colombo L; Haughie S
Hum Vaccin Immunother; 2023 Aug; 19(2):2227034. PubMed ID: 37344371
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design.
Zimmerman RK; Dauer K; Clarke L; Nowalk MP; Raviotta JM; Balasubramani GK
Hum Vaccin Immunother; 2023 Dec; 19(1):2177461. PubMed ID: 36809982
[TBL] [Abstract][Full Text] [Related]
3. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
[TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
Zimmerman RK; Patricia Nowalk M; Dauer K; Clarke L; Raviotta JM; Balasubramani GK
Vaccine; 2023 Aug; 41(35):5134-5140. PubMed ID: 37474406
[TBL] [Abstract][Full Text] [Related]
5. Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial".
Hadigal S; Colombo L; Haughie S
Hum Vaccin Immunother; 2022 Nov; 18(5):2085470. PubMed ID: 35674507
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.
Dunkle LM; Izikson R; Patriarca P; Goldenthal KL; Muse D; Callahan J; Cox MMJ;
N Engl J Med; 2017 Jun; 376(25):2427-2436. PubMed ID: 28636855
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
[TBL] [Abstract][Full Text] [Related]
8. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.
Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Bresee JS; Fry AM; Jernigan DB
MMWR Recomm Rep; 2017 Aug; 66(2):1-20. PubMed ID: 28841201
[TBL] [Abstract][Full Text] [Related]
9. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
Grohskopf LA; Blanton LH; Ferdinands JM; Chung JR; Broder KR; Talbot HK; Morgan RL; Fry AM
MMWR Recomm Rep; 2022 Aug; 71(1):1-28. PubMed ID: 36006864
[TBL] [Abstract][Full Text] [Related]
10. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.
Grohskopf LA; Alyanak E; Broder KR; Blanton LH; Fry AM; Jernigan DB; Atmar RL
MMWR Recomm Rep; 2020 Aug; 69(8):1-24. PubMed ID: 32820746
[TBL] [Abstract][Full Text] [Related]
11. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.
Grohskopf LA; Alyanak E; Broder KR; Walter EB; Fry AM; Jernigan DB
MMWR Recomm Rep; 2019 Aug; 68(3):1-21. PubMed ID: 31441906
[TBL] [Abstract][Full Text] [Related]
12. Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.
Manley HJ; Lacson EK; Aweh G; Chen Li N; Weiner DE; Miskulin DC; Hsu CM; Kapoian T; Hayney MS; Meyer KB; Johnson DS
Am J Kidney Dis; 2022 Sep; 80(3):309-318. PubMed ID: 35288216
[TBL] [Abstract][Full Text] [Related]
13. Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years.
Yin JK; Pepin S; van Aalst R; Loiacono MM; Samson SI
Hum Vaccin Immunother; 2022 Nov; 18(6):2106749. PubMed ID: 35914122
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.
Dawood FS; Naleway AL; Flannery B; Levine MZ; Murthy K; Sambhara S; Gangappa S; Edwards L; Ball S; Grant L; Belongia E; Bounds K; Cao W; Gross FL; Groom H; Fry AM; Rentz Hunt D; Jeddy Z; Mishina M; Kim SS; Wesley MG; Spencer S; Thompson MG; Gaglani M
Clin Infect Dis; 2021 Dec; 73(11):1973-1981. PubMed ID: 34245243
[TBL] [Abstract][Full Text] [Related]
15. Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
Hsiao A; Hansen J; Nunley KV; Lewis N; Selmani A; Inamdar A; Mallett-Moore T; Izikson R; Rudin D; Klein NP
Vaccine; 2022 Jan; 40(5):774-779. PubMed ID: 34998605
[TBL] [Abstract][Full Text] [Related]
16. National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
Tsai SY; Yeh TY; Chiu NC; Huang CT
Vaccine; 2022 Jun; 40(26):3701-3704. PubMed ID: 35577629
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 Season.
Izurieta HS; Lu M; Kelman J; Lu Y; Lindaas A; Loc J; Pratt D; Wei Y; Chillarige Y; Wernecke M; MaCurdy TE; Forshee R
Clin Infect Dis; 2021 Dec; 73(11):e4251-e4259. PubMed ID: 33211809
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
Gaglani M; Vasudevan A; Raiyani C; Murthy K; Chen W; Reis M; Belongia EA; McLean HQ; Jackson ML; Jackson LA; Zimmerman RK; Nowalk MP; Monto AS; Martin ET; Chung JR; Spencer S; Fry AM; Flannery B
Clin Infect Dis; 2021 Apr; 72(7):1147-1157. PubMed ID: 32006430
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness.
Chung JR; Flannery B; Gaglani M; Smith ME; Reis EC; Hickey RW; Jackson ML; Jackson LA; Belongia EA; McLean HQ; Martin ET; Segaloff HE; Kim SS; Patel MM
JAMA Pediatr; 2020 Jul; 174(7):705-713. PubMed ID: 32364599
[TBL] [Abstract][Full Text] [Related]
20. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
Woo EJ; Moro PL
Vaccine; 2021 Mar; 39(13):1812-1817. PubMed ID: 33678452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
